These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23637579)

  • 81. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
    Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
    Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.
    Henrich LM; Rogol AD; D'Amour P; Levine MA; Hanks JB; Bruns DE
    Clin Chem; 2006 Dec; 52(12):2286-93. PubMed ID: 17105782
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism.
    Cho ME; Duan Z; Chamberlain CE; Reynolds JC; Ring MS; Mannon RB
    Transplant Proc; 2010 Nov; 42(9):3554-8. PubMed ID: 21094814
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.
    Palmer SC; Craig JC; Navaneethan SD; Tonelli M; Pellegrini F; Strippoli GF
    Ann Intern Med; 2012 Aug; 157(4):263-75. PubMed ID: 22910937
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet.
    Apostolou T; Damianou L; Kotsiev V; Drakopoulos S; Hadjiconstantinou V
    Clin Nephrol; 2006 May; 65(5):374-7. PubMed ID: 16724661
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
    Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
    Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
    Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M
    PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality?
    Vervloet MG; du Buf-Vereijken PW; Potter van Loon BJ; Manamley N; Reichert LJ; Smak Gregoor PJ
    Neth J Med; 2013 Sep; 71(7):348-54. PubMed ID: 24038560
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
    Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
    Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Outcomes of cinacalcet withdrawal in Australian dialysis patients.
    Ruderman I; Holt SG; Kirkland GS; Maslen S; Hawley CM; Oliver V; Krishnasamy R; Gray NA; Talaulikar GS; Nelson CL; Rajaram Y; Gock H; Au E; Elder GJ; Mainra R; Toussaint ND
    Intern Med J; 2019 Jan; 49(1):48-54. PubMed ID: 29992701
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients.
    Sharma AK; Masterson R; Holt SG; Tan SJ; Hughes PD; Chu M; Jayadeva P; Toussaint ND
    Nephrology (Carlton); 2016 Jan; 21(1):46-54. PubMed ID: 26072678
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients.
    Bashir SO; Omer HA; Aamer MA; Somialy R; Morsy MD
    Saudi J Kidney Dis Transpl; 2015 Nov; 26(6):1135-41. PubMed ID: 26586050
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet.
    Seager CM; Srinivas TR; Flechner SM
    Ann Transplant; 2013 Jan; 18():31-5. PubMed ID: 23792498
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis.
    Yeung WG; Palmer SC; Strippoli GFM; Talbot B; Shah N; Hawley CM; Toussaint ND; Badve SV
    Am J Kidney Dis; 2023 Nov; 82(5):543-558. PubMed ID: 37356648
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Parathyroidectomy or cinacalcet: Do we still not know the best option for graft function in kidney-transplanted patients? A meta-analysis.
    Frey S; Goronflot T; Kerleau C; Gourraud PA; Caillard C; Hourmant M; Mirallié É; Figueres L
    Surgery; 2021 Sep; 170(3):727-735. PubMed ID: 33810851
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cinacalcet as symptomatic treatment of hypercalcaemia in primary hyperparathyroidism prior to surgery.
    Misiorowski W; Zgliczyński W
    Endokrynol Pol; 2017; 68(3):306-310. PubMed ID: 28660989
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Discovery of LNP1892: A Precision Calcimimetic for the Treatment of Secondary Hyperparathyroidism.
    Shukla MR; Sadasivam G; Sarde A; Sayyed M; Pachpute V; Phadtare R; Walke N; Chaudhari VD; Loriya R; Khan T; Gote G; Pawar C; Tryambake M; Mahajan N; Gandhe A; Sabde S; Pawar S; Patil V; Modi D; Mehta M; Nigade P; Modak V; Ghodke R; Narasimham L; Bhonde M; Gundu J; Goel R; Shah C; Kulkarni S; Sharma S; Bakhle D; Kamboj RK; Palle VP
    J Med Chem; 2023 Jul; 66(14):9418-9444. PubMed ID: 37442941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.